Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

NCT00257478 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00257478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00257478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
March 31, 2007
Enrollment
Not reported
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of prostate, cancer of the prostate, prostate cancer, prostatic cancer